RU2006144448A - Пролекарства пирролилпиримидиновых ингибиторов протеинкиназы erk - Google Patents
Пролекарства пирролилпиримидиновых ингибиторов протеинкиназы erk Download PDFInfo
- Publication number
- RU2006144448A RU2006144448A RU2006144448/04A RU2006144448A RU2006144448A RU 2006144448 A RU2006144448 A RU 2006144448A RU 2006144448/04 A RU2006144448/04 A RU 2006144448/04A RU 2006144448 A RU2006144448 A RU 2006144448A RU 2006144448 A RU2006144448 A RU 2006144448A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- compound according
- cancer
- disease
- aliphatic group
- Prior art date
Links
- 102000001253 Protein Kinase Human genes 0.000 title abstract 2
- 108060006633 protein kinase Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 14
- 238000000034 method Methods 0.000 claims abstract 9
- 239000000203 mixture Substances 0.000 claims abstract 8
- 201000010099 disease Diseases 0.000 claims abstract 6
- 125000001931 aliphatic group Chemical group 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 5
- 239000001301 oxygen Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 229910052717 sulfur Chemical group 0.000 claims 5
- 239000011593 sulfur Chemical group 0.000 claims 5
- 210000001072 colon Anatomy 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001118 alkylidene group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 210000003800 pharynx Anatomy 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042135 Stomatitis necrotising Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000133 brain stem Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000003849 large cell carcinoma Diseases 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000008585 noma Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000010198 papillary carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 210000002105 tongue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 claims 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- LWDDMZUJDCTNGH-BEWYTNLXSA-N CCC(C1)([C@H]1OP(O)(O)=O)Nc1ncc(C)c(-c2c[nH]c(C(N[C@H](CO)c3cccc(Cl)c3)=O)c2)n1 Chemical compound CCC(C1)([C@H]1OP(O)(O)=O)Nc1ncc(C)c(-c2c[nH]c(C(N[C@H](CO)c3cccc(Cl)c3)=O)c2)n1 LWDDMZUJDCTNGH-BEWYTNLXSA-N 0.000 description 1
- YVLGZCUTCQXTQS-MUMRKEEXSA-N CCC(CO)Nc1ncc(C)c(-c2c[nH]c(C(N[C@H](CCOP(O)(O)=O)c3cccc(Cl)c3)=O)c2)n1 Chemical compound CCC(CO)Nc1ncc(C)c(-c2c[nH]c(C(N[C@H](CCOP(O)(O)=O)c3cccc(Cl)c3)=O)c2)n1 YVLGZCUTCQXTQS-MUMRKEEXSA-N 0.000 description 1
- ZXLFUIDFBFNHSD-JRFVFWCSSA-N CC[C@H](CO)Nc1ncc(C)c(-c2c[nH]c(C(N[C@H](COC([C@H](C(C)C)NC)=O)c3cccc(Cl)c3)=O)c2)n1 Chemical compound CC[C@H](CO)Nc1ncc(C)c(-c2c[nH]c(C(N[C@H](COC([C@H](C(C)C)NC)=O)c3cccc(Cl)c3)=O)c2)n1 ZXLFUIDFBFNHSD-JRFVFWCSSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57128304P | 2004-05-14 | 2004-05-14 | |
| US60/571,283 | 2004-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006144448A true RU2006144448A (ru) | 2008-06-20 |
Family
ID=35159977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006144448/04A RU2006144448A (ru) | 2004-05-14 | 2005-05-13 | Пролекарства пирролилпиримидиновых ингибиторов протеинкиназы erk |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7358258B2 (https=) |
| EP (1) | EP1753744B1 (https=) |
| JP (1) | JP4993604B2 (https=) |
| KR (1) | KR20070012555A (https=) |
| CN (1) | CN1976925A (https=) |
| AT (1) | ATE435858T1 (https=) |
| AU (1) | AU2005245877B2 (https=) |
| BR (1) | BRPI0511124A (https=) |
| CA (1) | CA2566444A1 (https=) |
| DE (1) | DE602005015319D1 (https=) |
| IL (1) | IL179206A0 (https=) |
| MX (1) | MXPA06013208A (https=) |
| NO (1) | NO20065762L (https=) |
| NZ (1) | NZ551583A (https=) |
| RU (1) | RU2006144448A (https=) |
| UA (1) | UA84929C2 (https=) |
| WO (1) | WO2005113546A1 (https=) |
| ZA (1) | ZA200610163B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
| US8119667B2 (en) * | 2005-12-29 | 2012-02-21 | Schering-Plough Animal Health Corporation | Carbonates of fenicol antibiotics |
| JP2009528280A (ja) | 2006-02-16 | 2009-08-06 | シェーリング コーポレイション | Ｅｒｋインヒビターとしてのピロリジン誘導体 |
| US8716483B2 (en) | 2008-02-21 | 2014-05-06 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| JP2013147428A (ja) * | 2010-04-27 | 2013-08-01 | Dainippon Sumitomo Pharma Co Ltd | 新規２−ヘテロアリール単環ピリミジン誘導体 |
| CN103617111A (zh) * | 2011-04-01 | 2014-03-05 | 北京奇虎科技有限公司 | 一种计算机功耗计算方法及装置 |
| MX371331B (es) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk). |
| ME03336B (me) | 2013-03-12 | 2019-10-20 | Vertex Pharma | Inhibitori dnk-pk |
| JP6408569B2 (ja) | 2013-10-17 | 2018-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 |
| US20160264536A1 (en) | 2013-10-23 | 2016-09-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN107849046B (zh) * | 2015-06-03 | 2020-06-12 | 常州捷凯医药科技有限公司 | 作为erk抑制剂的杂环化合物 |
| BR112017026159A2 (pt) * | 2015-06-15 | 2018-08-14 | Asana Biosciences, Llc | inibidores heterocíclicos de erk1 e erk2 e seu uso no tratamento de câncer |
| EP3518931A4 (en) | 2016-09-27 | 2020-05-13 | Vertex Pharmaceuticals Incorporated | METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5776954A (en) * | 1996-10-30 | 1998-07-07 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
| US6989385B2 (en) * | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| US7304061B2 (en) * | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| US7361665B2 (en) * | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
-
2005
- 2005-05-13 AU AU2005245877A patent/AU2005245877B2/en not_active Expired - Fee Related
- 2005-05-13 BR BRPI0511124-2A patent/BRPI0511124A/pt not_active IP Right Cessation
- 2005-05-13 NZ NZ551583A patent/NZ551583A/en unknown
- 2005-05-13 CA CA002566444A patent/CA2566444A1/en not_active Abandoned
- 2005-05-13 DE DE602005015319T patent/DE602005015319D1/de not_active Expired - Lifetime
- 2005-05-13 UA UAA200613207A patent/UA84929C2/ru unknown
- 2005-05-13 RU RU2006144448/04A patent/RU2006144448A/ru not_active Application Discontinuation
- 2005-05-13 JP JP2007513409A patent/JP4993604B2/ja not_active Expired - Fee Related
- 2005-05-13 MX MXPA06013208A patent/MXPA06013208A/es not_active Application Discontinuation
- 2005-05-13 WO PCT/US2005/016801 patent/WO2005113546A1/en not_active Ceased
- 2005-05-13 CN CNA2005800214194A patent/CN1976925A/zh active Pending
- 2005-05-13 AT AT05756023T patent/ATE435858T1/de not_active IP Right Cessation
- 2005-05-13 US US11/129,114 patent/US7358258B2/en not_active Expired - Fee Related
- 2005-05-13 KR KR1020067026319A patent/KR20070012555A/ko not_active Withdrawn
- 2005-05-13 ZA ZA200610163A patent/ZA200610163B/en unknown
- 2005-05-13 EP EP05756023A patent/EP1753744B1/en not_active Expired - Lifetime
-
2006
- 2006-11-13 IL IL179206A patent/IL179206A0/en unknown
- 2006-12-13 NO NO20065762A patent/NO20065762L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005113546A1 (en) | 2005-12-01 |
| JP4993604B2 (ja) | 2012-08-08 |
| IL179206A0 (en) | 2007-03-08 |
| JP2007537293A (ja) | 2007-12-20 |
| US7358258B2 (en) | 2008-04-15 |
| AU2005245877A1 (en) | 2005-12-01 |
| AU2005245877B2 (en) | 2010-06-03 |
| EP1753744B1 (en) | 2009-07-08 |
| CN1976925A (zh) | 2007-06-06 |
| CA2566444A1 (en) | 2005-12-01 |
| EP1753744A1 (en) | 2007-02-21 |
| BRPI0511124A (pt) | 2007-11-27 |
| KR20070012555A (ko) | 2007-01-25 |
| NO20065762L (no) | 2007-02-12 |
| NZ551583A (en) | 2009-05-31 |
| DE602005015319D1 (de) | 2009-08-20 |
| US20060058318A1 (en) | 2006-03-16 |
| ATE435858T1 (de) | 2009-07-15 |
| UA84929C2 (en) | 2008-12-10 |
| MXPA06013208A (es) | 2007-01-16 |
| ZA200610163B (en) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3000422T3 (en) | Nitrile-containing compounds for use as medicaments | |
| RU2006144448A (ru) | Пролекарства пирролилпиримидиновых ингибиторов протеинкиназы erk | |
| CA2566461A1 (en) | Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto | |
| EP1651162B1 (en) | Improved cytotoxic agents comprising new maytansinoids | |
| JP3727613B2 (ja) | インドロカルバゾール誘導体を含有する前立腺病理疾患の治療薬 | |
| JP2025114536A (ja) | 免疫調節剤としての１，２，４－オキサジアゾールおよびチアジアゾール化合物 | |
| KR100747436B1 (ko) | 이소인돌-이미드 화합물 | |
| RU2007147382A (ru) | Соединения, являющиеся ингибиторами raf, и способы их применения | |
| MX2015004757A (es) | Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos. | |
| JP7162915B2 (ja) | 置換ピラゾロ［１，５－ａ］ピリミジン系大環状化合物 | |
| EA017345B1 (ru) | Производные лептомицина | |
| JP2019500413A (ja) | プロテインキナーゼ阻害剤及びその調製方法と医薬用途 | |
| CN107427497A (zh) | 作为免疫调节剂的3‑取代的1,3,4‑噁二唑和噻二唑化合物 | |
| RU2004109812A (ru) | Ингибиторы цистеинпротеазы 2-циано-4-аминопиримидинового строения с ингибирующим действием на катепсин к для лечения воспалительных и других заболеваний | |
| TW200401635A (en) | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof | |
| JP2019500413A5 (https=) | ||
| RU2013122898A (ru) | Похоксимовые конъюгаты, применимые для лечения связанных с hsp90 патологий, композиция и способ лечения с их помощью | |
| CN118647408A (zh) | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 | |
| WO2015197006A1 (zh) | 一种取代的氨基酸硫酯类化合物、其组合物及应用 | |
| CA2649762C (en) | Synthesis and uses of pyroglutamic acid derivatives | |
| CN112062804B (zh) | 沙蟾毒精衍生物及其制备方法、药物组合物与应用 | |
| WO2024153149A1 (zh) | 一种抗体药物偶联物、制备方法及其应用 | |
| WO2012112919A1 (en) | Stromal derived factor inhibition and cxcr4 blockade | |
| EP4710946A1 (en) | Multi-projectile antibody-drug conjugate, and preparation method therefor and use thereof | |
| WO2025149667A1 (en) | Antibody drug conjugates and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20091001 |